Subscribe
Interview with the Innovators

PYLARIFY Imaging in High-Risk Prostate Cancer

Interview with the Innovators
PET/CT Imaging in Prostate Cancer Patients
Steven Rowe, MD, PhD
Radiology and Radiological Science
Johns Hopkins Medicine,
Baltimore, MD
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.

Related Articles

Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans
By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD
Videos
Interview with the Innovators
Predicting High-Risk Disease Using Progression of Disease in 24 Months (POD24) and the Key Role of Repeat Biopsy to Exclude the Diagnosis of Transformation to a High-Grade Lymphoma in Patients with Relapsed Follicular Lymphoma
By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD
Videos
Interview with the Innovators
Broadening the Variety of Candidate Therapies for R/R Follicular Lymphoma Allows Optimal Personalized Rx Choice, While Patient-Directed Education Helps Attain Greatest Clinical Benefit
By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD
Videos
Interview with the Innovators
Criteria Used to Guide Treatment Decisions and Choice of Therapeutic Agents in Patients with Relapsed or Refractory Follicular Lymphoma
By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD
Videos
Interview with the Innovators
CONNECT
Subscribe
Sign Up for Oncology News

Subscribe to recieve the free, monthly OPM print publication and OPM weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.